Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$101.18

3.33 (3.40%)

10:04
04/13/18
04/13
10:04
04/13/18
10:04

Blueprint Medicines treatment of certain lung cancers granted FDA orphan status

Blueprint Medicines' small molecule rearranged during transfection inhibitor was granted orphan designation by the FDA as a treatment of rearranged during transfection-rearranged non-small cell lung cancer, JAK1/2-positive NSCLC, or TRKC-positive NSCLC, according to a post to the agency's website. Reference Link

BPMC Blueprint Medicines
$101.18

3.33 (3.40%)

11/01/17
ADAM
11/01/17
NO CHANGE
Target $80
ADAM
Buy
Blueprint Medicines price target raised to $80 from $66 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Blueprint Medicines to $80 from $66 ahead of two meaningful clinical trial updates that are due out by year-end. She continues to view the company's pipeline of novel, rationally designed, targeted kinase inhibitors as attractive and reiterated her Buy rating on Blueprint Medicines shares.
11/06/17
WEDB
11/06/17
NO CHANGE
Target $82
WEDB
Outperform
Blueprint Medicines price target raised to $82 from $70 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Blueprint Medicines to $82 from $70 after data in ASH abstract shows BLU-285 benefit in multiple mastocytosis burden measures that appear comparatively better than that achievable with midostaurin. The analyst expects ASH presentation to confirm high response rates that support an accelerated registration path. He reiterates an Outperform rating on the shares.
12/11/17
JMPS
12/11/17
NO CHANGE
Target $97
JMPS
Outperform
Blueprint Medicines price target raised to $97 from $88 at JMP Securities
After Blueprint Medicines presented updated Phase I data for avapritinib in patients with advanced systemic mastocytosis during the American Society of Hematology meeting, JMP Securities analyst Michael King raised his price target on the stock to $97 from $88, stating that robust clinical efficacy was demonstrated while the safety and tolerability profile was consistent with prior experience. The analyst, who sees an increased probability of success for avapritinib in the advanced systemic mastocytosis indication, keeps an Outperform rating on Blueprint shares.
12/11/17
GSCO
12/11/17
NO CHANGE
Target $99
GSCO
Buy
Blueprint Medicines price target rasied to $99 from $82 at Goldman Sachs
Goldman analyst Terence Flynn raised Buy rated Blueprint Medicines' price target to $99 from $82 to reflect the probability of success for BLU-285 and BLU-667 and M&A potential.

TODAY'S FREE FLY STORIES

KRYS

Krystal Biotech

$17.14

0.08 (0.47%)

06:52
07/16/18
07/16
06:52
07/16/18
06:52
Conference/Events
Krystal Biotech management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 25

    Jul

XOP

SPDR Oil Exploration and Production Fund

$43.19

0.06 (0.14%)

06:52
07/16/18
07/16
06:52
07/16/18
06:52
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:51
07/16/18
07/16
06:51
07/16/18
06:51
Hot Stocks
Bank of America reports Q2 average loan balances in business segments up 5% »

Average loan balances in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$26.43

0.89 (3.48%)

06:51
07/16/18
07/16
06:51
07/16/18
06:51
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$102.95

0.17 (0.17%)

, TEVA

Teva

$23.29

-0.45 (-1.90%)

06:51
07/16/18
07/16
06:51
07/16/18
06:51
Recommendations
Neurocrine, Teva analyst commentary  »

Neurocrine price target…

NBIX

Neurocrine

$102.95

0.17 (0.17%)

TEVA

Teva

$23.29

-0.45 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

  • 16

    Sep

UGAZ

VelocityShares 3x Long Natural Gas ETN

$54.61

-2.06 (-3.64%)

06:50
07/16/18
07/16
06:50
07/16/18
06:50
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:50
07/16/18
07/16
06:50
07/16/18
06:50
Hot Stocks
Bank of America reports Q2 NII up 6% to $11.7B »

Reflecting benefits from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

ERJ

Embraer

$21.50

-0.78 (-3.50%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Periodicals
Embraer sees demand for 10,550 smaller jets in next 20 years, Reuters reports »

Brazil's Embraer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

EPRT

Essential Properties Realty Trust

$14.00

(0.00%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Initiation
Essential Properties Realty Trust initiated  »

Essential Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$34.05

0.67 (2.01%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNTR

Venator Materials

$16.76

0.07 (0.42%)

, TROX

Tronox

$19.31

-0.28 (-1.43%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Hot Stocks
Venator Materials to acquire European paper laminates business from Tronox »

Venator Materials (VNTR)…

VNTR

Venator Materials

$16.76

0.07 (0.42%)

TROX

Tronox

$19.31

-0.28 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 08

    Aug

PSA

Public Storage

$228.07

-1.43 (-0.62%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Downgrade
Public Storage rating change  »

Public Storage downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

EFA

iShares MSCI EAFE Index Fund

$67.80

0.21 (0.31%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Hot Stocks
Bank of America reports Q2 return on average assets 1.17% »

Reports Q2 return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

BRO

Brown & Brown

$28.76

0.025 (0.09%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Hot Stocks
Brown & Brown subsidiary acquires Professional Disability Associates »

J. Scott Penny, Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

JNK

SPDR Barclays High Yield Bond

$35.69

(0.00%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCI

Intra-Cellular

$20.45

-0.11 (-0.54%)

06:47
07/16/18
07/16
06:47
07/16/18
06:47
Conference/Events
Intra-Cellular management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SJB

ProShares Short High Yield

$22.95

-0.055 (-0.24%)

06:47
07/16/18
07/16
06:47
07/16/18
06:47
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSUR

OraSure

$17.32

0.01 (0.06%)

06:46
07/16/18
07/16
06:46
07/16/18
06:46
Downgrade
OraSure rating change  »

OraSure downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

NEP

NextEra Energy Partners

$45.91

-0.51 (-1.10%)

06:46
07/16/18
07/16
06:46
07/16/18
06:46
Downgrade
NextEra Energy Partners rating change  »

NextEra Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.63

0.005 (0.01%)

06:46
07/16/18
07/16
06:46
07/16/18
06:46
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:46
07/16/18
07/16
06:46
07/16/18
06:46
Earnings
Bank of America reports Q2 EPS 63c, consensus 57c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.76

0.16 (0.14%)

06:46
07/16/18
07/16
06:46
07/16/18
06:46
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$191.32

0.19 (0.10%)

06:45
07/16/18
07/16
06:45
07/16/18
06:45
Periodicals
Samsung patent could rival Apple Watch technology, Business Insider reports »

After applying for the…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$191.32

0.19 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TLT

iShares 20+ Year Treasury Bond Fund

$122.74

0.33 (0.27%)

06:45
07/16/18
07/16
06:45
07/16/18
06:45
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.